XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting - Significant Segment Expenses (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting [Abstract]        
Sales $ 409,268 $ 221,484 $ 750,532 $ 492,624
Cost of sales (excluding depreciation expense) 158,171 73,125 275,437 161,657
Research and development expense 89,217 665,517 1,048,380 1,080,780
Other research and development expense [1] 1,325,212 1,310,358 3,334,521 2,665,826
Total research and development expense 1,414,429 1,975,875 4,382,901 3,746,606
Sales and marketing expense 984,977 975,190 1,893,544 1,275,677
General and administrative expense 1,616,972 1,611,817 3,339,685 3,114,621
Depreciation and amortization expense 86,285 67,628 171,138 138,856
Total operating expenses 4,102,663 4,630,510 9,787,268 8,275,760
Total other expense, net (734,356) (204,173) (1,174,776) (341,041)
Loss before income taxes (4,585,922) (4,686,324) (10,486,949) (8,285,834)
Income tax benefit 0 (1,750) (4,188) (1,750)
Net loss $ (4,585,922) $ (4,684,574) $ (10,482,761) $ (8,284,084)
[1] Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.